Ric N Price1, Anne-Catrin Uhlemann1, Alan Brockman1, Rose McGready1, Elizabeth Ashley1, Lucy Phaipun1, Rina Patel1, Kenneth Laing1, Sornchai Looareesuwan1, Nicholas J White1, François Nosten1, Sanjeev Krishna1. 1. Department of Cellular and Molecular Medicine-Infectious Diseases, St George's Hospital Medical School, London, UK (S Krishna DPhil, K Laing PhD, Rina Patel BSc, A-C Uhlemann MD); Centre for Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Headington, Oxford, UK (E Ashley MD, R McGready PhD, F Nosten PhD, RN Price MD, NJ White DSc); Shoklo Malaria Research Unit, Mae Sod, Tak Province, Thailand (E Ashley MD, A Brockman BSc, R McGready PhD, F Nosten PhD, L Phaipun); Menzies School of Health Research Charles Darwin University, Darwin, Australia (RN Price MD); Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand (S Looareesuwan MD, NJ White DSc).
Abstract
BACKGROUND: The borders of Thailand harbour the world's most multidrug resistant Plasmodium falciparum parasites. In 1984 mefloquine was introduced as treatment for uncomplicated falciparum malaria, but substantial resistance developed within 6 years. A combination of artesunate with mefloquine now cures more than 95% of acute infections. For both treatment regimens, the underlying mechanisms of resistance are not known. METHODS: The relation between polymorphisms in the P falciparum multidrug resistant gene 1 (pfmdr1) and the in-vitro and in-vivo responses to mefloquine were assessed in 618 samples from patients with falciparum malaria studied prospectively over 12 years. pfmdr1 copy number was assessed by a robust real-time PCR assay. Single nucleotide polymorphisms of pfmdr1, P falciparum chloroquine resistance transporter gene (pfcrt) and P falciparum Ca2+ ATPase gene (pfATP6) were assessed by PCR-restriction fragment length polymorphism. FINDINGS: Increased copy number of pfmdr1 was the most important determinant of in-vitro and in-vivo resistance to mefloquine, and also to reduced artesunate sensitivity in vitro. In a Cox regression model with control for known confounders, increased pfmdr1 copy number was associated with an attributable hazard ratio (AHR) for treatment failure of 6.3 (95% CI 2.9-13.8, p<0.001) after mefloquine monotherapy and 5.4 (2.0-14.6, p=0.001) after artesunate-mefloquine therapy. Single nucleotide polymorphisms in pfmdr1 were associated with increased mefloquine susceptibility in vitro, but not in vivo. INTERPRETATION: Amplification in pfmdr1 is the main cause of resistance to mefloquine in falciparum malaria. RELEVANCE TO PRACTICE: Multidrug resistant P falciparum malaria is common in southeast Asia, but difficult to identify and treat. Genes that encode parasite transport proteins maybe involved in export of drugs and so cause resistance. In this study we show that increase in copy number of pfmdr1, a gene encoding a parasite transport protein, is the best overall predictor of treatment failure with mefloquine. Increase in pfmdr1 copy number predicts failure even after chemotherapy with the highly effective combination of mefloquine and 3 days' artesunate. Monitoring of pfmdr1 copy number will be useful in epidemiological surveys of drug resistance in P falciparum, and potentially for predicting treatment failure in individual patients.
BACKGROUND: The borders of Thailand harbour the world's most multidrug resistant Plasmodium falciparum parasites. In 1984 mefloquine was introduced as treatment for uncomplicated falciparum malaria, but substantial resistance developed within 6 years. A combination of artesunate with mefloquine now cures more than 95% of acute infections. For both treatment regimens, the underlying mechanisms of resistance are not known. METHODS: The relation between polymorphisms in the P falciparum multidrug resistant gene 1 (pfmdr1) and the in-vitro and in-vivo responses to mefloquine were assessed in 618 samples from patients with falciparum malaria studied prospectively over 12 years. pfmdr1 copy number was assessed by a robust real-time PCR assay. Single nucleotide polymorphisms of pfmdr1, P falciparum chloroquine resistance transporter gene (pfcrt) and P falciparum Ca2+ ATPase gene (pfATP6) were assessed by PCR-restriction fragment length polymorphism. FINDINGS: Increased copy number of pfmdr1 was the most important determinant of in-vitro and in-vivo resistance to mefloquine, and also to reduced artesunate sensitivity in vitro. In a Cox regression model with control for known confounders, increased pfmdr1 copy number was associated with an attributable hazard ratio (AHR) for treatment failure of 6.3 (95% CI 2.9-13.8, p<0.001) after mefloquine monotherapy and 5.4 (2.0-14.6, p=0.001) after artesunate-mefloquine therapy. Single nucleotide polymorphisms in pfmdr1 were associated with increased mefloquine susceptibility in vitro, but not in vivo. INTERPRETATION: Amplification in pfmdr1 is the main cause of resistance to mefloquine in falciparum malaria. RELEVANCE TO PRACTICE: Multidrug resistant P falciparum malaria is common in southeast Asia, but difficult to identify and treat. Genes that encode parasite transport proteins maybe involved in export of drugs and so cause resistance. In this study we show that increase in copy number of pfmdr1, a gene encoding a parasite transport protein, is the best overall predictor of treatment failure with mefloquine. Increase in pfmdr1 copy number predicts failure even after chemotherapy with the highly effective combination of mefloquine and 3 days' artesunate. Monitoring of pfmdr1 copy number will be useful in epidemiological surveys of drug resistance in P falciparum, and potentially for predicting treatment failure in individual patients.
Authors: M T Duraisingh; P Jones; I Sambou; L von Seidlein; M Pinder; D C Warhurst Journal: Mol Biochem Parasitol Date: 2000-04-30 Impact factor: 1.759
Authors: J A Simpson; R Price; F ter Kuile; P Teja-Isavatharm; F Nosten; T Chongsuphajaisiddhi; S Looareesuwan; L Aarons; N J White Journal: Clin Pharmacol Ther Date: 1999-11 Impact factor: 6.875
Authors: Susan M Thomas; Omar Ndir; Therese Dieng; Souleymane Mboup; David Wypij; James H Maguire; Dyann F Wirth Journal: Am J Trop Med Hyg Date: 2002-05 Impact factor: 2.345
Authors: Eline L Korenromp; Brian G Williams; Eleanor Gouws; Christopher Dye; Robert W Snow Journal: Lancet Infect Dis Date: 2003-06 Impact factor: 25.071
Authors: C M Wilson; S K Volkman; S Thaithong; R K Martin; D E Kyle; W K Milhous; D F Wirth Journal: Mol Biochem Parasitol Date: 1993-01 Impact factor: 1.759
Authors: R N Price; C Cassar; A Brockman; M Duraisingh; M van Vugt; N J White; F Nosten; S Krishna Journal: Antimicrob Agents Chemother Date: 1999-12 Impact factor: 5.191
Authors: Ric N Price; Anne-Catrin Uhlemann; Michele van Vugt; Al Brockman; Robert Hutagalung; Shalini Nair; Denae Nash; Pratap Singhasivanon; Tim J C Anderson; Sanjeev Krishna; Nicholas J White; François Nosten Journal: Clin Infect Dis Date: 2006-04-26 Impact factor: 9.079
Authors: C T Happi; G O Gbotosho; O A Folarin; A Sowunmi; T Hudson; M O'Neil; W Milhous; D F Wirth; A M J Oduola Journal: Antimicrob Agents Chemother Date: 2008-12-15 Impact factor: 5.191